| Dr Marcus Peter Kennedy, MD | |
|
4301 W Markham St, Mail Slot 555, Little Rock, AR 72205-7199 | |
| (501) 686-5525 | |
| (501) 686-7893 |
| Full Name | Dr Marcus Peter Kennedy |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 4301 W Markham St, Little Rock, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932246170 | NPI | - | NPPES |
| 07090022400 | Other | AR | QUALCHOICE |
| P00405677 | Other | AR | RAILROAD MEDICARE |
| 5N843 | Other | AR | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | E-5260 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marcus Peter Kennedy, MD 4301 W Markham St, Mail Slot 555, Little Rock, AR 72205-7199 Ph: (501) 686-5525 | Dr Marcus Peter Kennedy, MD 4301 W Markham St, Mail Slot 555, Little Rock, AR 72205-7199 Ph: (501) 686-5525 |
News Archive
AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
The federal judge who shot down a Medicaid work requirement plan last June remained deeply skeptical Thursday of the Trump administration's renewed strategy to force enrollees to work.
Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.
Investigators at the University of British Columbia/Centre for Molecular Medicine & Therapeutics and BC Children's Hospital have examined more than 25 years of data to reveal new insights into predicting the age of onset for Huntington disease.
The production of a certain kind of brain cell that had been considered an impediment to healing may actually be needed to staunch bleeding and promote repair after a stroke or head trauma, researchers at Duke Medicine report.
› Verified 8 days ago
Lonnie E Harrison, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7 Shackleford West Blvd, Little Rock, AR 72211 Phone: 501-664-5860 Fax: 501-664-0889 | |
Muthu Veera Kumaran, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 556, Little Rock, AR 72205 Phone: 501-686-6033 Fax: 501-686-8932 | |
Armaghan Yunis Soomro, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1701 S Shackleford Rd, Little Rock, AR 72211 Phone: 501-219-7282 Fax: 201-277-9765 | |
Tanvi Harishbhai Patel, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 508, Little Rock, AR 72205 Phone: 501-686-7105 Fax: 501-526-5906 | |
Gaurav Dhar, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 783, Little Rock, AR 72205 Phone: 501-686-8000 | |
Anthony R Giglia Iii, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5800 W 10th St, Ste 610 Freeway Medical Center, Little Rock, AR 72204 Phone: 501-661-9393 Fax: 501-663-4795 | |
Brian Bean, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: #2 St Vincent Circle, Little Rock, AR 72205 Phone: 501-552-3592 Fax: 501-552-4129 |